The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1282
March 24, 2008
View Complete Issue         Table of Contents 2019 
A Rivastigmine Patch for Dementia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
A Rivastigmine Patch for Dementia
March 24, 2008 (Issue: 1282)
Cholinesterase inhibitors are now used routinely in patients with dementia. Rivastigmine transdermal system (Exelon Patch - Novartis), a patch formulation of the cholinesterase inhibitor rivastigmine tartrate, has been approved by the FDA for...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: A Rivastigmine Patch for Dementia
Article code: 1282a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.